ANDA 216250, held by Novitium Pharma. Lidocaine Hydrochloride.
As of Nov 16, 2026, ANDA 216250 (Lidocaine Hydrochloride), held by Novitium Pharma, was first approved by FDA on Mar 23, 2022, with 0 approved supplements and 0 published complete response letters.
INDICATIONS Lidocaine hydrochloride is indicated for the production of topical anesthesia of accessible mucous membranes of the oral and nasal cavities and proximal portions of the digestive tract.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 23, 2022 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Lidocaine Hydrochloride4% · solution;topical | Lidocaine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters